- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00558623
Dietary Calcium Supplementation to Reduce Blood Lead in Pregnancy
Controlled Trial in Pregnancy of Dietary Supplements for Suppression of Bone Resorption and Mobilization of Lead Into Plasma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Recent evidence indicates that there is a marked increase in the mobilization of lead from maternal bone stores into circulation during pregnancy and lactation. Furthermore, data from our group and others indicate that this phenomenon carries a significant risk of fetal toxicity in the form of growth (decreased birth weight, head circumference, birth length) and subsequent cognitive development. These findings pose a major public health problem, even among societies with declining lead exposure, given the persistence of pockets of high lead exposure (including some communities living in proximity to hazardous waste) as well as the long residence time of lead in bone (years to decades). One possible strategy for suppressing the mobilization of maternal bone lead stores during pregnancy is nutritional intervention. We are conducting a randomized, double-blinded, placebo-controlled trial of dietary supplements containing 1,200 milligrams of calcium as a means of suppressing bone resorption and the resulting mobilization of lead from bone into plasma during pregnancy, and into breast milk during the postpartum period. We are taking maternal measurements of pre-pregnancy and postpartum bone lead using our K-x-ray fluorescence technology; bone resorption (by assaying N-telopeptide of type I collagen in urine [urinary NTX]), whole blood lead, and plasma lead (using special collection techniques and measured by IDTIMS) during pre-pregnancy, the first, second, third trimesters and at one and four months postpartum; and breast milk lead levels at one and four months postpartum.
We are measuring maternal plasma and breast milk lead levels as these are the most direct sources of fetal and infant lead exposures, and recent research suggests that maternal venous blood lead levels do not adequately reflect either of these parameters. We are testing the hypothesis that supplements will significantly decrease urinary NTX, plasma lead, and breast milk lead levels. We are also exploring the relationship of plasma lead levels to birth anthropometry measures. This research, if successful, may provide a means of preventing secondary toxicity from accumulated lead burdens among women of reproductive age.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Morelos
-
Cuernavaca, Morelos, Mexico, 62100
- Mauricio Hernandez-Avila
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- being in the first trimester of pregnancy (no more than 14 weeks gestation); not presenting with a high-risk pregnancy; residing and plans to reside in the metropolitan Mexico City area for approximately 5 years; agreeing to participate and signing the informed consent form.
Exclusion Criteria:
- high-risk pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: 1
Placebo
|
daily supplement of 1,200 milligrams calcium (two-600 mg tablets calcium carbonate at bedtime)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Blood Lead Concentration, Plasma Lead Concentration
Time Frame: 2nd, 3rd trimester pregnancy and 1,4,7,12 months postpartum
|
2nd, 3rd trimester pregnancy and 1,4,7,12 months postpartum
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Urinary Cross-linked N-telopeptides (marker of bone resorption)
Time Frame: 2nd, 3rd trimester of pregnancy and 1,4,7,12 months postpartum
|
2nd, 3rd trimester of pregnancy and 1,4,7,12 months postpartum
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Howard Hu, MD, ScD, Harvard School of Public Health and University of Michigan
- Principal Investigator: Mauricio Hernandez-Avila, MD, ScD, National Institute of Public Health and Ministry of Health, Mexico
Publications and helpful links
General Publications
- Perng W, Tamayo-Ortiz M, Tang L, Sanchez BN, Cantoral A, Meeker JD, Dolinoy DC, Roberts EF, Martinez-Mier EA, Lamadrid-Figueroa H, Song PXK, Ettinger AS, Wright R, Arora M, Schnaas L, Watkins DJ, Goodrich JM, Garcia RC, Solano-Gonzalez M, Bautista-Arredondo LF, Mercado-Garcia A, Hu H, Hernandez-Avila M, Tellez-Rojo MM, Peterson KE. Early Life Exposure in Mexico to ENvironmental Toxicants (ELEMENT) Project. BMJ Open. 2019 Aug 26;9(8):e030427. doi: 10.1136/bmjopen-2019-030427.
- Ettinger AS, Lamadrid-Figueroa H, Mercado-Garcia A, Kordas K, Wood RJ, Peterson KE, Hu H, Hernandez-Avila M, Tellez-Rojo MM. Effect of calcium supplementation on bone resorption in pregnancy and the early postpartum: a randomized controlled trial in Mexican women. Nutr J. 2014 Dec 16;13(1):116. doi: 10.1186/1475-2891-13-116.
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P10345/9910CONT
- NIEHS P42-ES05947 (Project 1)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pregnancy
-
Far Eastern Memorial HospitalCompletedCornual PregnancyTaiwan
-
Peking Union Medical College HospitalPeking Union Medical CollegeUnknownPregnancy | Pregnancy Related | Infant | Pregnancy Disease | Risk FactorChina
-
Centre Hospitalier Universitaire de Saint EtienneCompletedProlonged PregnancyFrance
-
University Hospital, ToursCompleted
-
Technische Universität DresdenWithdrawnPregnancy Trimester, Second | Pregnancy Trimester, First | Pregnancy Trimester, ThirdGermany
-
Ufuk UniversityNot yet recruitingPregnancy Complications | Pregnancy Loss | Pregnancy Preterm
-
Hadassah Medical OrganizationCompleted
-
Universitair Ziekenhuis BrusselMerck Serono International SAUnknownPregnancy | Pregnancy LossBelgium
-
Turku University HospitalUniversity of TurkuCompleted
-
Centre Hospitalier René DubosCompletedDeciduitis; Complicating Pregnancy
Clinical Trials on calcium carbonate
-
Unity Health TorontoCanadian Institutes of Health Research (CIHR)CompletedEnd-stage Renal DiseaseCanada
-
BayerRecruitingHealthy Volunteers | Heartburn | Indigestion | Stomach Acid Related Symptoms | Nocturnal Stomach Acid Related SymptomsUnited Kingdom
-
Karolinska University HospitalCompleted
-
Harvard School of Public Health (HSPH)Ifakara Health Institute; St. John's Research Institute; Africa Academy for Public...CompletedPregnancy RelatedTanzania, India
-
China Medical University HospitalRecruitingRheumatoid Arthritis | Osteopenia or OsteoporosisTaiwan
-
BayerCompleted
-
University of Colorado, DenverRecruitingAging | Vascular Stiffness | Vascular DilationUnited States
-
Gary StrikerCompleted
-
University College, LondonActive, not recruitingChronic Kidney DiseasesUnited Kingdom
-
Integrative Health Technologies, Inc.UnknownOsteopenia, OsteoporosisUnited States